Schoellhammer Carl M, Schroeder Avi, Maa Ruby, Lauwers Gregory Yves, Swiston Albert, Zervas Michael, Barman Ross, DiCiccio Angela M, Brugge William R, Anderson Daniel G, Blankschtein Daniel, Langer Robert, Traverso Giovanni
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Faculty of Chemical Engineering, Technion-Israel Institute of Technology, Haifa 32000, Israel.
Sci Transl Med. 2015 Oct 21;7(310):310ra168. doi: 10.1126/scitranslmed.aaa5937.
There is a significant clinical need for rapid and efficient delivery of drugs directly to the site of diseased tissues for the treatment of gastrointestinal (GI) pathologies, in particular, Crohn's and ulcerative colitis. However, complex therapeutic molecules cannot easily be delivered through the GI tract because of physiologic and structural barriers. We report the use of ultrasound as a modality for enhanced drug delivery to the GI tract, with an emphasis on rectal delivery. Ultrasound increased the absorption of model therapeutics inulin, hydrocortisone, and mesalamine two- to tenfold in ex vivo tissue, depending on location in the GI tract. In pigs, ultrasound induced transient cavitation with negligible heating, leading to an order of magnitude enhancement in the delivery of mesalamine, as well as successful systemic delivery of a macromolecule, insulin, with the expected hypoglycemic response. In a rodent model of chemically induced acute colitis, the addition of ultrasound to a daily mesalamine enema (compared to enema alone) resulted in superior clinical and histological scores of disease activity. In both animal models, ultrasound treatment was well tolerated and resulted in minimal tissue disruption, and in mice, there was no significant effect on histology, fecal score, or tissue inflammatory cytokine levels. The use of ultrasound to enhance GI drug delivery is safe in animals and could augment the efficacy of GI therapies and broaden the scope of agents that could be delivered locally and systemically through the GI tract for chronic conditions such as inflammatory bowel disease.
对于胃肠道(GI)疾病,特别是克罗恩病和溃疡性结肠炎的治疗,直接将药物快速有效地递送至病变组织部位存在重大临床需求。然而,由于生理和结构屏障,复杂的治疗性分子难以通过胃肠道递送。我们报道了使用超声作为增强药物向胃肠道递送的一种方式,重点是直肠递送。超声使模型治疗药物菊粉、氢化可的松和美沙拉嗪在离体组织中的吸收增加了两到十倍,这取决于在胃肠道中的位置。在猪身上,超声诱导了短暂的空化现象且加热可忽略不计,导致美沙拉嗪的递送增强了一个数量级,同时成功实现了大分子胰岛素的全身递送,并产生了预期的降血糖反应。在化学诱导的急性结肠炎啮齿动物模型中,在每日美沙拉嗪灌肠剂中添加超声(与单独灌肠相比)导致疾病活动的临床和组织学评分更高。在这两种动物模型中,超声治疗耐受性良好,组织破坏最小,在小鼠中,对组织学、粪便评分或组织炎症细胞因子水平没有显著影响。使用超声增强胃肠道药物递送在动物中是安全的,并且可以提高胃肠道治疗的疗效,并扩大可以通过胃肠道局部和全身递送用于慢性疾病(如炎症性肠病)的药物范围。